It exerts a wide range of protective effects on the GI tract, including: Aiding the healing of lesions Guarding against the harmful effects of drugs Maintaining the integrity of the gastrointestinal mucosa [810] Neuroprotection In cases where the brain or spine has been injured, the anti-inflammatory, angiogenic, and growth factor modulatory activities of BPC-157 are beneficial in preventing secondary damage and accelerating recovery
Most relevant peptides: Thymosin alpha-1 for immune rebalancing and Treg promotion KPV for TNF-alpha and IL-6 reduction BPC-157 for joint tissue repair and anti-inflammatory effects TB-500 for tendon and connective tissue repair Research shows that BPC-157 reduces inflammation in joint tissues relevant to RA
Conservative starting doses would be essential: Initial phase : Cagrilintide 0.3 mg + Tirzepatide 2.5 mg weekly Escalation : Increase cagrilintide by 0.3-0.6 mg every 4 weeks Tirzepatide adjustment : Maintain or modestly increase based on tolerance Monitoring : Close observation for cumulative GI effects This remains speculative, as no published trials have examined this specific combination
For example, people with Hashimoto's disease are likely also to have celiac disease or rheumatoid arthritis
- What is the expected treatment timeline
